Eris Lifesciences appoints Murari Ranganathan to spearhead Cardiometabolic Business

Mumbai, March 6, 2025: Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company has appointed Mr. Murari Ranganathan as President, Cardiometabolic Business. He will be based out of the company’s Mumbai office and take charge of the company’s Anti-Diabetes and Cardiology businesses.

Prior to joining Eris, Mr. Ranganathan was Commercial Director, Women’s Health, Metabolics, and International Business at Abbott India Limited. He joined Abbott in 2010 as Head Sales, Medical Nutrition and played a variety of roles in his 15-year stint with the Company. Prior to Abbott, he has worked with organisations like Baxter, Novo Nordisk, and Torrent Pharma. He has a bachelor’s in physics and mathematics from Bangalore University and has completed his Postgraduate Diploma in Marketing from St. Joseph College of Business Administration, Bangalore.

Welcoming Mr. Ranganathan, Mr. Amit Bakshi, Chairman and Managing Director, Eris Lifesciences said, “We are delighted to have Murari join our team. His extensive experience and domain expertise will be highly valuable in strengthening our position in our flagship Cardiometabolic franchise. I welcome him to Eris and wish him success.”

On his new appointment, Mr. Ranganathan, Eris Lifesciences said, “I’m excited to join Eris Lifesciences in its growth journey. Eris is the youngest among the Top-20 companies in the Indian Pharmaceutical Market with a dynamic and entrepreneurial culture. I look forward to working together with the team and set new benchmarks in disease management and patient care.”

Established in 2007, Eris Lifesciences is the youngest among the Top-20 pharma companies in India. With an annual branded formulations revenue of INR 3,000+ crore as per AWACS, Eris has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care. Eris manufactures a wide range of prescription products across several dosage forms including oral solids, oral liquids, softgels, ointments, sprays & gels, sterile injectables and biologics in its 6 manufacturing facilities, and markets these products across India through a network of 2,000+ stockists and 5,00,000+ retail pharmacies.

Eris’ operating revenue and profits have doubled in the last 5 years. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of ~ INR 4,000 crore over the last 3 years. For the first 9 months of financial year ending March 2025, the company reported a consolidated revenue of Rs 2,188 crore.